IGM Biosciences (IGMS) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1 year price objectives for IGM Biosciences' stock. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they expect the company's share price to reach $23.60 in the next twelve months. This suggests a possible upside of 251.7% from the stock's current price.
View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts.

IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS stock has decreased by 60.6% and is now trading at $6.71.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IGMS earnings forecast.

IGM Biosciences, Inc. (NASDAQ:IGMS) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.03. The business earned $0.45 million during the quarter, compared to analyst estimates of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. The company's quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.33) earnings per share.

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

(IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IGMS stock can currently be purchased for approximately $6.71.

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $391.66 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis.

The company employs 289 workers across the globe.

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.